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Summary
Objectives: We performed a prospective case—control study of bloodstream infections in order
to determine the infection rate of Acinetobacter baumannii and to determine the risk factors
associated with infection and mortality.
Methods: Between February 2004 and January 2005, 579 consecutive blood specimens were
collected from the two neonatal intensive care units (NICUs) of Al-Nasser and Al-Shifa hospitals in
Gaza City.
Results: Forty (6.9%) isolates of A. baumannii were obtained from neonates aged under 28 days.
Of the patients, 62.5% were male and 37.5% were female. Compared to matched, uninfected
controls, statistically significant risk factors were weight <1500 g (odds ratio (OR) 3.89,
p < 0.001), age <7 days (OR 2.33, p = 0.027), median hospitalization of =20 days (OR 3.1,
p = 0.003), mechanical ventilation (OR 3.5, p = 0.001), use of a central venous catheter (CVC;
OR 10.5, p < 0.001), and prior antibiotic use (OR 4.85, p = 0.003). The overall mortality was also
significantly different (overall mortality 37.5% in cases vs. 12% in uninfected controls; OR 4.4,
p = 0.001). Compared to infected controls, statistically significant risk factors were mechanical
ventilation (OR 2.68, p = 0.008), use of a CVC (OR 6.68, p < 0.001), and prior antibiotic use (OR
5.68, p = 0.001). The multidrug-resistant type was significantly associated with death in the
neonates ( p = 0.023). The isolates of A. baumannii were resistant to commonly used antibiotics,
while susceptible to meropenem (92.5%), imipenem (90%), ciprofloxacin (75%), gentamicin
(57.5%), and ceftriaxone (50%).
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Conclusions: The infection rate with multidrug-resistant A. baumannii is considerable and
alarming in NICU infants, and is associated with significant mortality.
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Newborns receiving care in neonatal intensive care units
(NICUs) are at an increased risk of nosocomial infections
because of immaturity of the immune system and barrier
functions of the skin and gastrointestinal tract, and the
invasive diagnostic and therapeutic procedures they
undergo.1 NICU patients are at high risk of nosocomial blood-
stream infections (NBSI) because of the high acuity care,
prolonged hospitalization, and frequent invasive procedures.
Previous studies have found the incidence of NBSI in NICUs to
vary between 5% and 32%.2
Multidrug-resistant (MDR) Acinetobacter baumannii has
recently been established as a leading nosocomial pathogen
in several hospitals.3,4 With the spread of multi-resistant
bacteria, the treatment of NBSI has become a challenging
task.5 Hospital outbreaks have been described from various
geographic areas,6,7 and this organism has become endemic
in some of them. Villegas and Hartstein reviewed Acineto-
bacter outbreaks occurring from 1977 to 2000 and hypothe-
sized that endemicity, increasing rate, and increasing new
resistance to antimicrobial drugs in a collection of isolates
suggest transmission.8
Almost 28 years ago, researchers observed acquired
resistance of A. baumannii to antimicrobial drugs com-
monly used at that time, among them aminopenicillins,
ureidopenicillins, first- and second-generation cephalos-
porins, cephamycins, most aminoglycosides, chloramphe-
nicol, and tetracyclines.9
In the current study we sought to determine the preva-
lence of A. baumannii infection in NICU patients, and to
assess the characteristics and risk factors for MDR A. bau-
mannii acquisition during hospitalization.
Materials and methods
Clinical setting
This study was conducted in the NICUs of Al-Shifa and Al-
Nasser pediatric hospitals. The NICU at Al-Shifa Hospital has a
capacity of 10 beds, while that of Al-Nasser Paediatric Hos-
pital has a capacity of eight beds, reserved for premature
neonates and neonates requiring intensive care such as
mechanical ventilation and cardiac support.
Design of the study
This was a case—control study conducted from February 2004
to January 2005. A consent form was signed by parents of the
neonates in compliance with the Helsinki Declaration and the
Palestinian Ministry of Health. Clinical data, including infor-
mation on demographic characteristics, length of hospital
stay, presence of catheters, invasive diagnostic and thera-
peutic procedures, parenteral nutrition, laboratory exami-
nations, antibiotic usage, Apgar score at 1 minute, and
mechanical ventilation were collected.Definitions
Sepsis caseswere defined as those neonates hospitalized in the
NICU who developed A. baumannii infection after 48 h of
admission to the NICU, confirmed by laboratory examinations.
Uninfected controls were those neonates hospitalized dur-
ing the same time period as the sepsis cases, matched for age
and birth weight, with no diagnosis of bloodstream infection.
Infected controls were those neonates who had acquired a
bloodstream infectionduringhospitalization, causedbyorgan-
isms other than A. baumannii. The uninfected and infected
controlswereused to identify risk factors, presenting signs and
symptoms, and outcomes specific to A. baumannii that may
facilitate and expedite diagnosis and intervention.
Microbiological analysis
Nursing staff obtained venous blood from NICU newborns by
means of aseptic techniques. Briefly 0.2 ml of blood were
drawn into bottles containing 10 ml of supplemented trypti-
case soy broth (Roche) and incubated at 37 8C. After 24 h,
blood cultures were subcultured conventionally on plates of
sheep blood agar, Chocolate agar, and MacConkey agar
(Difco) with aerobic incubation at 37 8C for 18—24 h. Where
the blood cultures were negative after incubation for 24 h,
inoculation into plates as mentioned above was repeated
over the course of a week. Isolates were identified as A.
baumannii by a negative oxidase test, catalase positive
reactions, and Analytical Profile Index (API 20NE) system
updated profile (Biomerieux SA, France). Other Gram-nega-
tive organisms were identified by API 20E and API 20NE, while
Gram-positive staphylococci and streptococci were identi-
fied by culture characteristics, catalase, coagulase activ-
ities, API 20 Staph, and API 20 Strep.
Multiple blood cultures yielding the same organism from
the same patient were considered to relate to a single
infection. The following variables were recorded: age, sex,
birth weight, and gestational age, and information on inten-
sive care procedures and treatment of bloodstream infec-
tion, based on the definitions of the Centers for Disease
Control and Prevention (CDC).10
The antibiotic susceptibilities of A. baumannii isolates
were determined by the disk diffusion method on Mueller—
Hinton agar plates, using calibrated inoculum of the isolates
based on McFarland standard, with the following antibiotics:
piperacillin, trimethoprim—sulfamethoxazole (SXT), cefo-
taxime, ceftriaxone, gentamicin, amikacin, ceftazidime,
ciprofloxacin, imipenem, and meropenem.11
We defined A. baumannii as MDR when the organism was
resistant to three antibiotics out of four of the following:
ceftazidime, ciprofloxacin, gentamicin, and imipenem.12
Data analysis
Data were analyzed using SPSS version 13 (SPSS, Inc.,
Chicago, IL, USA). Potential risk factors were assessed by
Table 1 Demographic and clinical characteristics of neo-
nates infected with Acinetobacter baumannii (N = 40)
Characteristics Neonates
that
survived
(n = 25)
Neonates
that died
(n = 15)
p-Value
Age
7 days 15 (60) 6 (40)
<7 days 10 (40) 9 (60) 0.22
Sex
Male 15 (60) 10 (66.7) 0.67
Female 10 (40) 5 (33.3)
Antibiotype
Multi-resistant 6 (24) 9 (60) 0.023
Susceptible 19 (76) 6 (40)
Antibiotic treatment
Appropriate 19 (76) 3 (20)
Inappropriate 6 (24) 8 (53.3) 0.01a
No antibiotics - 4 (26.7) -
Clinical and laboratory signs
Hypothermia 6 (24) 8 (53.3) 0.06
Jaundice 8 (32) 4 (26.7) 1.0a
Anemia 9 (36) 10 (66.7) 0.06
Thrombocytopenia 12 (48) 9 (60) 0.46
Leukopenia 8 (32) 11 (73.3) 0.011
Median of hospitalization
20 days 15 (60) 10 (66.7) 0.67
12 days 2 (8) 3 (20) 0.34a
8 days 8 (32) 2 (13.3) 0.27a
Maternal status
Hypertension 9 (36) 7 (46.7) 0.5
Diabetes mellitus 5 (20) 2 (13.3) 0.69
Urinary tract infection 10 (40) 7 (46.7) 0.68
Premature rupture of
the membranes
1 (4) 3 (20) 0.14a
Results are n (%).
a Fisher’s exact test.
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analyzed using Pearson’s Chi-square or Fisher’s exact test. All
tests were two-tailed with p < 0.05 considered significant.
Results
Patient characteristics
During the period February 2004 to January 2005, blood
specimens from 579 neonates of Al-Nasser and Al-Shifa
hospital NICUs in Gaza City were collected for isolation
of A. baumannii. During this period, 40 cases of A. bau-
mannii infection were reported from neonates aged less
than 28 days; the incidence was 6.9%. Of the cases, 92.5%
were recorded from Al-Shifa Hospital and 7.5% from Al-
Nasser NICU. Case patients were similar to their matched
control patients with respect to mean age (under 28 days);
the patient group had a median age of 8.0 days, while the
control group had a median age of 10.0 days. The distribu-
tion of cases during the study period (monthly) showed the
highest occurrence during the months of April, July, and
September.
Univariate analysis of the study patient characteristics of
those neonates that survived and those that died was under-
taken to assess the prognostic factors for Acinetobacter
infection and their association with mortality (Table 1).
Inappropriate antibiotic treatment and multi-resistant
type were significantly associated with death: 22.2% (8/36)
and 22.5% (9/40) of the patients, respectively. In addition,
there was an association between leukopenia and mortality
(27.5%). No statistical significance was found with regard to
age, sex, hospital stay, maternal status, and other clinical
and laboratory signs (hypothermia, jaundice, anemia, throm-
bocytopenia).
Organisms
In the current study, the pathogens other than A. baumannii
isolated among bacteremic cases were Escherichia coli (27,
5.0%), Staphylococcus aureus (17, 3.1%), Klebsiella spp (16,
3.0%), coagulase-negative staphylococci (15, 2.8%), Entero-
bacter spp (9, 1.7%), Streptococcus spp (8, 1.5%), Citrobacter
spp (7, 1.3%), and Pseudomonas aeruginosa (7, 1.3%).
Risk factors
Risk factors and outcome (death) associated with cases of A.
baumannii sepsis versus uninfected controls are shown in
Table 2. Case patients were significantly more likely to have
received mechanical ventilation (OR 3.5), had prior use of
antibiotics (OR 4.85), and had a central venous catheter
(CVC; OR 10.5). In addition case patients were more likely
to have had a birth weight of<1500 g (OR 3.89), age <7 days
(OR 2.33), and a median of hospitalization of = 20 days (OR
3.1). Several other variables had a tendency to be more
associated with case patients, but the values did not reach
statistical significance, such as weeks of gestation, sex, and
Apgar score at 1 minute <7. The overall crude mortality rate
was 15/40 (37.5%), with an OR of 4.4.
Similarly, the risk factors and outcome (sepsis-related
death) associated with cases of A. baumannii sepsis versus
matched infected controls are displayed in Table 3. Factorssignificantly associated with cases were prior use of anti-
biotics (OR 5.68, p = 0.001), use of a CVC (OR 6.68,
p < 0.001), mechanical ventilation (OR 2.68, p = 0.008),
and sepsis-related death (OR 3.94, p = 0.001). Other factors
also appeared to be more associated with sepsis cases, but
the values did not reach statistical significance.
Antibiotic susceptibility
The antibiotic susceptibility pattern showed 92.5% of the
isolates were susceptible to meropenem, 90% to imipenem,
75% to ciprofloxacin, 57.5% to gentamicin, and 50% to
Table 2 Bivariate risk factors and outcome associated with cases of Acinetobacter baumannii sepsis versus uninfected controls
Risk factors Cases (n = 40) Uninfected controls
(n = 100)
OR p-Value
Weight at birth
1500 g 15 (37.5) 70 (70)
<1500 g 25 (62.5) 30 (30) 3.89 0.001
Sex
Female 15 (37.5) 45 (45)
Male 25 (62.5) 55 (55) 1.36 0.42
Age
7 days 21 (52.5) 72 (72)
<7 days 19 (47.5) 28 (28) 2.33 0.027
Weeks of gestation
26—29 5 (12.5) 15 (15) 0.81 0.70
30—33 10 (25) 25 (25) 1.0 1.0
34—36 25 (62.5) 60 (60) 1.11 0.78
Median of hospitalization
=20 days 25 (62.5) 35 (35) 3.1 0.003
=12 days 5 (12.5) 23 (23) 0.48 0.16
=8 days 10 (25) 42 (42) 0.46 0.06
Mode of delivery
Vaginal 28 (70) 67 (67) 1.15 0.73
Cesarean 12 (30) 33 (33)
Premature rupture of the membranes 4 (10) 13 (13) 0.74 0.78a
Apgar score at 1 minute
7 21 (52.5) 67 (67)
<7 19 (47.5) 33 (33) 1.8 0.11
Prior antibiotic use 36 (90) 65 (65) 4.85 0.003
Utilization of central venous catheter 29 (72.5) 20 (20) 10.5 0.001
Mechanical ventilation 24 (60) 30 (30) 3.5 0.001
Clinical outcome
Death 15 (37.5) 12 (12) 4.4 0.001
Results are n (%).
a Fisher’s exact test.
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cefotaxime, ceftazidime, SXT, and piperacillin were 37.5%,
35%, 30%, 22.5%, and 10%, respectively. Despite a small
number of bacterial strains being resistant to imipenem
and meropenem, 15 strains from both hospitals were con-
sidered MDR, which constituted 37.5% of the total isolated
strains.
Discussion
Acinetobacter species have emerged as important nosoco-
mial pathogens that are often MDR and associated with
life-threatening infections.13 A. baumannii, a clinically
important species has a tendency toward cross-transmis-
sion, particularly in ICUs, where numerous outbreaks have
been encountered.14To the best of our knowledge, this study is the first to focus
on septicemia in NICUs in Gaza City. The present study was
conducted to determine the prevalence of A. baumannii as
well as to identify risk factors for acquisition of MDR A.
baumannii present in the NICU.
The prevalence rate in this study was 6.9% of the total
bloodstream samples (579) collected in the NICU over a 1-
year period, with 37.5% death due to A. baumannii.
Several risk factors showed an association with the devel-
opment of A. baumannii infection and sepsis-related death.
The most predominant risk factors with a statistically signifi-
cant association were submission to invasive procedures,
mechanical ventilation, utilization of a CVC, and the presence
of conditions such as very low birth weight. These same
risk factors have been described previously.3,15 A. baumannii
sepsis in the NICU was associated with a significant risk of
Table 3 Bivariate risk factors and outcome associated with cases of Acinetobacter baumannii sepsis versus infected controls
Risk factors Cases (n = 40) Infected controls
(n = 106)
OR p-Value
Weight at birth
1500 g 15 (37.5) 45 (42.5)
<1500 g 25 (62.5) 61 (57.5) 1.23 0.59
Sex
Female 15 (37.5) 43 (40.6)
Male 25 (62.5) 63 (59.4) 1.14 0.74
Age
7 days 21 (52.5) 68 (64.2)
<7 days 19 (47.5) 38 (35.8) 1.62 0.2
Weeks of gestation
26—29 5 (12.5) 28 (26.4) 0.4 0.073
30—33 10 (25) 23 (21.7) 1.2 0.67
34—36 25 (62.5) 55 (51.9) 1.5 0.25
Median of hospitalization
=20 days 25 (62.5) 48 (45.3) 2.0 0.064
=12 days 5 (12.5) 26 (24.5) 0.44 0.11
=8 days 10 (25) 32 (30.2) 0.77 0.54
Mode of delivery
Vaginal 28 (70) 76 (71.7) 0.92 0.84
Cesarean 12 (30) 30 (28.3)
Premature rupture of the membranes 4 (10) 13 (12.3) 0.79 1.0a
Apgar score at 1 minute
7 21 (52.5) 62 (58.5)
<7 19 (47.5) 44 (41.5) 1.27 0.51
Prior antibiotic use 36 (90) 65 (61.3) 5.68 0.001
Utilization of central venous catheter 29 (72.5) 30 (28.3) 6.68 0.001
Mechanical ventilation 24 (60) 38 (35.8) 2.68 0.008
Clinical outcome
Sepsis-related death 15 (37.5) 14 (13.2) 3.94 0.001
Results are n (%).
a Fisher’s exact test.
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infection controlmeasures, but rather it couldbeattributed to
the occurrence of MDR strains. Inappropriate therapy was
significantly associated with death in 22.2% (8/36) of neo-
nates. The studyalso revealed thatMDRA. baumannii typeand
leukopeniawere significantly associatedwithmortality. These
findings are consistent with other recent studies.16,17
In vitro susceptibility tests showed that meropenem and
imipenem were the most effective drugs against A. bauman-
nii isolates in Palestine, while susceptibility to third- or
fourth-generation cephalosporins and ciprofloxacin varied
considerably. Although ciprofloxacin is not recommended
in the treatment of neonates, it was used because of the
lack of an alternative in a life-threatening situation.The high MDR A. baumannii rate (37.5%) found in this study
may be associated with the high frequency at which these
antimicrobial drugs were used for both the prophylactic and
therapeutic treatment of hospitalized newborns. This prac-
tice may have exerted selective pressures leading to the
emergence of MDR strains,18,19 which in turn may have
stimulated the acquisition of genes encoding resistance
mechanisms via horizontal transfer mechanisms between
environments. It is of particular interest that in this study
a significant number of patients received antimicrobial drugs
before positive blood culture presentation (empiric use), due
to clinical manifestations suggestive of a bloodstream infec-
tion. A progressive decrease in the effectiveness of third-
generation cephalosporins against Acinetobacter has been
628 A.M.K. Al Jarousha et al.coupled with the increased use of these antibiotics.13,20 We
re-emphasize that intravenous broad-spectrum antibiotics
should be used with caution. Ceftazidime and/or cefotaxime
use should be discontinued in units where resistant strains for
these two antibiotics are being increasingly reported. With
regard to ceftazidime- and cefotaxime-resistant strains in
our study, the hospital ICU was advised to use other antibiotic
combinations like an effective beta-lactam or carbapenem
(imipenem) along with amikacin. The combined use of var-
ious antibiotics would be judicious.
In conclusion, the MDR A. baumannii infection rate is
considerable and alarming in NICU infants, and is associated
with significant mortality. Risk factors include low birth
weight, the use of CVCs, mechanical ventilation, and prior
antibiotic use.
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